Articles with public access mandates - Stephan StilgenbauerLearn more
Not available anywhere: 27
Review
Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study
S Stilgenbauer, B Eichhorst, J Schetelig, S Coutre, JF Seymour, T Munir, ...
The lancet oncology 17 (6), 768-778, 2016
Mandates: US National Institutes of Health
Review
Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger …
O Hermine, E Hoster, J Walewski, A Bosly, S Stilgenbauer, C Thieblemont, ...
The Lancet 388 (10044), 565-575, 2016
Mandates: Lymphoma Research Foundation, USA
Review
Minimal residual disease assessment improves prediction of outcome in patients with chronic lymphocytic leukemia (CLL) who achieve partial response: comprehensive analysis of …
G Kovacs, S Robrecht, AM Fink, J Bahlo, P Cramer, J von Tresckow, ...
Journal of Clinical Oncology 34 (31), 3758-3765, 2016
Mandates: German Research Foundation, Federal Ministry of Education and Research, Germany
Review
Analysis of 11q22–q23 deletion target genes in B-cell chronic lymphocytic leukaemia: Evidence for a pathogenic role of NPAT, CUL5, and PPP2R1B
C Kalla, MO Scheuermann, I Kube, M Schlotter, D Mertens, H Döhner, ...
European journal of cancer 43 (8), 1328-1335, 2007
Mandates: German Research Foundation
Review
TP53 mutation and survival in aggressive B cell lymphoma
T Zenz, M Kreuz, M Fuge, W Klapper, H Horn, AM Staiger, D Winter, ...
International Journal of Cancer 141 (7), 1381-1388, 2017
Mandates: Canadian Institutes of Health Research
Review
Richter transformation in chronic lymphocytic leukemia (CLL)—a pooled analysis of German CLL Study Group (GCLLSG) front line treatment trials
O Al-Sawaf, S Robrecht, J Bahlo, AM Fink, P Cramer, J v Tresckow, ...
Leukemia 35 (1), 169-176, 2021
Mandates: German Research Foundation
Review
Optimising outcomes for patients with chronic lymphocytic leukaemia on ibrutinib therapy: European recommendations for clinical practice
JG Gribben, F Bosch, F Cymbalista, CH Geisler, P Ghia, P Hillmen, ...
British journal of haematology 180 (5), 666-679, 2018
Mandates: US National Institutes of Health, Cancer Research UK, Wellcome Trust
Review
Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial
AJM Ferreri, K Cwynarski, E Pulczynski, CP Fox, E Schorb, C Celico, ...
Leukemia 36 (7), 1870-1878, 2022
Mandates: Swiss National Science Foundation, Cancer Research UK, Government of Italy
Review
Control of chronic lymphocytic leukemia development by clonally-expanded CD8+ T-cells that undergo functional exhaustion in secondary lymphoid tissues
BS Hanna, PM Roessner, H Yazdanparast, D Colomer, E Campo, ...
Leukemia 33 (3), 625-637, 2019
Mandates: German Research Foundation, Helmholtz Association, Government of Spain …
Review
PI3Kδ inhibition modulates regulatory and effector T-cell differentiation and function in chronic lymphocytic leukemia
BS Hanna, PM Roessner, A Scheffold, BMC Jebaraj, Y Demerdash, ...
Leukemia 33 (6), 1427-1438, 2019
Mandates: German Research Foundation, Federal Ministry of Education and Research, Germany
Review
Quantitative gene expression deregulation in mantle-cell lymphoma: correlation with clinical and biologic factors
D Kienle, T Katzenberger, G Ott, D Saupe, A Benner, H Kohlhammer, ...
Journal of clinical oncology 25 (19), 2770-2777, 2007
Mandates: German Research Foundation
Review
High efficacy of venetoclax plus obinutuzumab in patients with complex karyotype and chronic lymphocytic leukemia
O Al-Sawaf, E Lilienweiss, J Bahlo, S Robrecht, AM Fink, M Patz, ...
Blood, The Journal of the American Society of Hematology 135 (11), 866-870, 2020
Mandates: German Research Foundation, Federal Ministry of Education and Research, Germany
Review
Chronic lymphocytic leukemia with mutated IGHV4-34 receptors: shared and distinct immunogenetic features and clinical outcomes
A Xochelli, P Baliakas, I Kavakiotis, A Agathangelidis, LA Sutton, E Minga, ...
Clinical Cancer Research 23 (17), 5292-5301, 2017
Mandates: Swedish Research Council, European Commission, Government of Italy
Review
NFATC1 activation by DNA hypomethylation in chronic lymphocytic leukemia correlates with clinical staging and can be inhibited by ibrutinib
C Wolf, A Garding, K Filarsky, J Bahlo, S Robrecht, N Becker, M Zucknick, ...
International journal of cancer 142 (2), 322-333, 2018
Mandates: German Research Foundation, Federal Ministry of Education and Research, Germany
Review
Oxidative stress as candidate therapeutic target to overcome microenvironmental protection of CLL
DY Yosifov, I Idler, N Bhattacharya, M Reichenzeller, V Close, D Ezerina, ...
Leukemia 34 (1), 115-127, 2020
Mandates: German Research Foundation, Helmholtz Association
Review
17p deletion in chronic lymphocytic leukemia: risk stratification and therapeutic approach
A Schnaiter, S Stilgenbauer
Hematology/Oncology Clinics 27 (2), 289-301, 2013
Mandates: German Research Foundation
Review
MDM4 is targeted by 1q gain and drives disease in Burkitt lymphoma
J Hüllein, M Słabicki, M Rosolowski, A Jethwa, S Habringer, K Tomska, ...
Cancer research 79 (12), 3125-3138, 2019
Mandates: Helmholtz Association, European Commission
Review
Targeting inhibitor of apoptosis proteins by S mac mimetic elicits cell death in poor prognostic subgroups of chronic lymphocytic leukemia
D Opel, A Schnaiter, D Dodier, M Jovanovic, A Gerhardinger, I Idler, ...
International journal of cancer 137 (12), 2959-2970, 2015
Mandates: German Research Foundation
Review
The regulatory interaction of EVI1 with the TCL1A oncogene impacts cell survival and clinical outcome in CLL
E Vasyutina, JM Boucas, J Bloehdorn, C Aszyk, G Crispatzu, ...
Leukemia 29 (10), 2003-2014, 2015
Mandates: German Research Foundation
Review
Time-to-progression after front-line fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy for chronic lymphocytic leukaemia: a retrospective, multicohort study
CD Herling, KR Coombes, A Benner, J Bloehdorn, LL Barron, ZB Abrams, ...
The Lancet Oncology 20 (11), 1576-1586, 2019
Mandates: US National Institutes of Health
Publication and funding information is determined automatically by a computer program